Before Hurricane Helene closed it in September 2024, Baxter’s North Cove plant made roughly 60% of the intravenous solution used in U.S. hospitals every day, about 1.5 million bags, according to the American Hospital Association. One plant, most of a country’s supply. This post sets out verified 2024 to 2026 IV market figures across solutions, equipment, home infusion, hydration clinics and memberships.
IV Market Statistics
How Big Is The IV Market In 2026?
No firm sizes the whole IV market one way. Grand View Research tracks IV solutions, home infusion therapy and IV hydration therapy as three separate revenue markets, each under its own scope definition.
BCC Research takes a wider cut, sizing IV therapy and venous access devices together at $57.0 billion in 2024 and projecting $74.4 billion by 2029 at a 5.5% CAGR. The segments below overlap that figure and each other, so they cannot be summed.
| IV market segment | 2025 | 2026 | 2033 forecast | CAGR 2026-2033 |
|---|---|---|---|---|
| Home infusion therapy | $41.7B | $45.0B | $78.8B | 8.3% |
| IV solutions | $13.8B | $14.8B | $28.2B | 9.6% |
| IV hydration therapy | $2.8B | $3.0B | $5.7B | 9.2% |
Source: Grand View Research, market revenue, 2026-2033 report editions.
Home infusion leads because it is measured as a services market. Services made up 72.4% of its global revenue in 2025, anti-infectives were the largest application, and North America held 56.3%. The direction matches what Quantumrun sets out in its health forecasts for 2028, where monitoring and treatment keep moving out of hospital buildings.
Source: Grand View Research, home infusion therapy revenue shares, 2025.
IV Solutions Market Statistics And Supplier Concentration
Grand View Research puts global IV solutions revenue at $14.8 billion in 2026. North America held 40.8% of 2025 revenue, total parenteral nutrition held 66.6% by type, and the home segment was the largest end use. The U.S. market alone was $4.9 billion in 2025 and an estimated $5.2 billion in 2026.
Estimates diverge. Global Market Insights values the same global market at $14.8 billion in 2025, a full year earlier, and forecasts $32.3 billion by 2035 at 8.2%. SNS Insider put 2025 at $13.35 billion. Base years and scope definitions differ, so the three cannot be blended.
Supply sits in few hands. Global Market Insights reports Baxter International led with over 18% of 2025 revenue, and that Baxter, Fresenius Kabi, Kelun, B. Braun and Otsuka together held 55%.
Source: Global Market Insights, intravenous solutions market shares, 2025.
That concentration showed in October 2024, days after the North Cove shutdown, when Premier Inc. polled its provider members.
| Premier member survey finding | Share of respondents | Respondents |
|---|---|---|
| Experiencing IV fluid shortages | More than 86% | 228 |
| Holding 10 days of supply or less | About 54% | 228 |
| Postponed elective and other procedures | Nearly 17% | 235 |
| Considering postponing procedures | 58% | 235 |
| Implemented fluid conservation protocols | More than 81% | 257 |
| Solicited by gray market suppliers | More than 40% | 255 |
Source: Premier Inc. IV fluids member survey, October 7-8, 2024. Self-selected survey of Premier member providers; respondent counts differ by question.
The shortage ran nearly a year. In August 2025 the FDA declared the sodium chloride 0.9% injection shortage resolved and removed those products from its Drug Shortage Database, noting other IV fluids remained listed. Those products had been in shortage since 2018.
IV Equipment Market Statistics 2026
Mordor Intelligence sizes IV equipment at $17.34 billion in 2026, up from $16.34 billion in 2025, reaching $23.36 billion by 2031 at a 6.13% CAGR. Its scope excludes IV solutions and drugs, parenteral nutrition included, which is why the number sits below broader estimates.
Four leading 2025 revenue shares, each measured against total IV equipment revenue on a different segmentation axis and therefore not additive: IV catheters 37.78% by product type, hospitals 48.62% by end user, medication administration 43.92% by application, North America 41.85% by geography.
Source: Mordor Intelligence, IV equipment revenue shares, 2025.
Growth sits elsewhere. Asia-Pacific leads regions at a 7.96% CAGR to 2031 and chemotherapy and oncology applications follow at 7.72%. Home-care settings expand at 6.97% and smart infusion pumps at 6.67%, both ahead of the 6.13% market baseline.
That move out of hospitals runs alongside the automation Quantumrun covers in automated medication handling.
Source: Mordor Intelligence, forecast CAGRs, 2026-2031.
IV Hydration Therapy Market Statistics
The elective side sells drips for energy, immunity and recovery through clinics, franchises and mobile nurses. Grand View Research puts global revenue at $3.0 billion in 2026 and North America at $1.44 billion.
| IV hydration therapy | 2025 | 2026 | 2033 forecast | CAGR 2026-2033 |
|---|---|---|---|---|
| Global | $2.8B | $3.0B | $5.7B | 9.2% |
| North America | $1.35B | $1.44B | $2.56B | 8.6% |
Source: Grand View Research, IV hydration therapy revenue, 2026-2033 report editions.
Mordor Intelligence sizes the same category at $2.94 billion in 2025, reaching $4.60 billion by 2030 at an 8.90% CAGR. The two firms use different scopes and forecast horizons.
Which IV Drip Segments Grow Fastest?
NAD+ protocols lead every formulation at a 15.2% CAGR to 2030. Mobile and concierge services lead service settings at 12.8%, athletic performance drips lead applications at 11.4%, and Asia Pacific leads regions at 9.3%. All four beat the 8.90% category baseline.
Source: Mordor Intelligence, forecast CAGRs, 2025-2030.
Incumbent shares are measured against a 2024 base year, again on separate axes: vitamin cocktails 44.6% by infusion type, in-clinic medical spas 46.3% by service setting, wellness and preventive care 38.7% by application, North America 39.6% by geography. Mordor reports the top five brands hold under 25% of global revenue. Longevity marketing drives much of the NAD+ demand, a theme Quantumrun examines in its piece on synthetic age reversal.
Source: Mordor Intelligence, IV hydration therapy revenue shares, 2024.
How Big Is The IV Therapy Membership Market?
The Business Research Company sizes IV therapy memberships at $2.16 billion in 2026, up from $1.94 billion in 2025, reaching $3.32 billion by 2030 at an 11.4% CAGR. That is the fastest published growth rate of any IV segment covered here.
Source: The Business Research Company, IV therapy membership market revenue, 2025-2030.
How Many Patients Receive IV Therapy?
U.S. hospitals recorded 35,658,583 admissions in the 2024 American Hospital Association Annual Survey, published in February 2026. Community hospitals accounted for 33,553,725 of those. The survey counted 6,100 hospitals and 907,216 staffed beds.
Source: American Hospital Association, Fast Facts on U.S. Hospitals, 2026 edition, 2024 survey data.
Device use is measured differently. StatPearls reports roughly 300 million peripheral IV catheters placed annually in the U.S., with up to 80% of adult and 70% of pediatric hospitalized patients requiring one. That is a share of patients receiving a device, not a count of admissions, and the two figures should not be multiplied. Vascular access is one of the areas Quantumrun tracks in its healthcare predictions for 2030, alongside work on AI and patient outcomes.
Source: StatPearls, NCBI Bookshelf, updated July 6, 2025.
Two markets, moving at different speeds. Clinical demand tracks admissions and chronic disease. Consumer demand tracks wellness spending and grows faster on every published measure, which is why consumer-facing health data and automated emergency response sit in the same forecasts.
FAQs
How big is the IV market in 2026?
Grand View Research puts IV solutions at $14.8 billion and home infusion therapy at $45.0 billion in 2026. Mordor Intelligence puts IV equipment at $17.34 billion. Scopes overlap, so the figures cannot be added together.
Is the IV fluid shortage over, as Reddit threads keep asking?
For saline, yes. The FDA declared the sodium chloride 0.9% injection shortage resolved in August 2025 and removed those products from its Drug Shortage Database. The agency noted other IV fluids remained on the shortage list at that time.
Which IV market segment is growing fastest?
IV therapy memberships, at an 11.4% CAGR to 2030 per The Business Research Company. Within hydration clinics, Mordor Intelligence forecasts NAD+ protocols at 15.2% and mobile or concierge services at 12.8% through 2030.
Why do Reddit users say one company controls the IV fluid supply?
Because concentration is real. Global Market Insights reports Baxter International held over 18% of 2025 global IV solutions revenue, and the top five suppliers held 55% combined. Baxter’s North Cove plant alone made about 60% of daily U.S. supply.
How many hospitalized patients get an IV?
StatPearls reports up to 80% of adult and 70% of pediatric hospitalized patients require a peripheral IV catheter, with roughly 300 million placed annually in the U.S. U.S. hospitals logged 35,658,583 admissions in the 2024 AHA survey.
Sources
https://www.aha.org/statistics/fast-facts-us-hospitals
https://premierinc.com/newsroom/blog/premier-inc-data-more-than-86-percent-of-providers-experiencing-shortages-of-iv-fluids-in-aftermath-of-october-hurricanes
https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-marty-makary-md-mph-announcing-resolution-iv-saline-solutions-shortage
https://www.ncbi.nlm.nih.gov/books/NBK525988/
